USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 26, 2024 /PRNewswire/ -- USA News Group News Commentary – Immunotherapy is transforming oncology by harnessing the immune system's power to fight cancer like never before. Notable advancements include a bioengineered therapeutic platform that boosts immune responses, providing targeted solutions for challenging cancer types. Researchers have also introduced an mRNA-based immunotherapy platform capable of selectively tar ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 23, 2024 /PRNewswire/ -- USA News Group News Commentary – Recent advancements in cancer treatment continue to underscore the transformative potential of innovative therapies to improve patient outcomes. A stage 4 breast cancer patient in the United States reportedly achieved complete remission within six weeks through a novel immunotherapy approach, as highlighted by the New York Post. Meanwhile, in Europe, a Scottish woman became the first rec ...

Promising BRACELET-1 results in HR+/HER2- metastatic breast cancer lay the foundation for potential registration-enabling study and accelerated approvalAdvancing gastrointestinal cancer pipeline underscores potential for additional registration-enabling studiesSAN DIEGO and CALGARY, AB, Dec. 23, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is providing a recap of the major accomplishments from 2024 and a ...

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 20, 2024 /PRNewswire/ -- USA News Group News Commentary – The American Cancer Society has published its Advances in Oncology – 2024 Research Highlights, underscoring major strides in cancer research and ongoing innovation. However, the optimism is tempered by a troubling finding: a significant global rise in early-onset colorectal cancer cases. This unsettling trend comes as the medical community grapples with the linge ...

SAN DIEGO  and CALGARY, AB, Dec. 18, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced the presentation of two data sets through two abstracts showcasing pelareorep's potential in difficult-to-treat gastrointestinal cancers were accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium in San Francisco January 23-25, 2025.Tom Hei ...

Condensed Interim Consolidated Financial Statements (unaudited) Oncolytics Biotech Inc. For the three and nine months ended September 30, 2024 ® ONCOLYTICS BIOTECH INC. CONDENSED INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (unaudited) (in thousands of Canadian dollars, except share amounts) | --- | --- | --- | --- | --- | |-----------------------------------------------------------------------------------------------------------------------------------------------|-------|----------------------|-- ...

BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms pelareorep + paclitaxel combination should be evaluated in a registrational studyUpcoming GOBLET milestones include updated efficacy data from anal cancer cohort and safety run-in data from the modified FOLFIRINOX pancreatic cancer cohortCash position of $19.6 million as of September 30, 2024Management hosting conference call and webcast today at 8:30 a.m. ETSAN DIEGO and CALGARY, AB, Nov. 12, 2024 /PRN ...

Conference call and webcast to take place on Tuesday, November 12, 2024, at 8:30 a.m. ETSAN DIEGO and CALGARY, AB, Nov. 11, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today announced that it will host a conference call and webcast on Tuesday, November 12, 2024, at 8:30 a.m. ET to discuss a corporate update and financial results for the third quarter 2024.Conference Call & WebcastDate: Tuesday, November ...

Shares of Oncolytics Biotech (ONCY) rallied 18.2% on Friday after the company announced that it is seeking an accelerated pathway for the approval of its lead developmental candidate, pelareorep, for the metastatic breast cancer (mBC) indication. The stock is also gaining today. Pelareorep follows a unique mechanism of action, different from currently available therapeutics for this indication. It selectively targets cancer cells, triggering a cascade of inflammatory responses (which include PDL1 upregulati ...

Recent clinical efficacy results from the BRACELET-1 trial in HR+/HER2- breast cancer pave the way for a clinical study designed to support an accelerated approval Key milestones in gastrointestinal cancer clinical trials expected in 2025, with potential for new registrationenabling studies SAN DIEGO and CALGARY, AB, Oct. 4, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, is issuing a corporate update to pr ...